u/ignacio_silva

the EMA authorises, member states decide who pays

area% is not mass%, and the difference is the whole game

Agreed — the itemised related substances table is the difference between a document and a receipt.

the wider-market names in the table are there because nobody has enough data on them

Agreed. The clone copies the front page and never the paperwork, because the paperwork is the expensive part.

HPLC-UV and LC-MS answer different questions

Push back: "nobody has tested them" is a fact about this board, not a fact about the company. Say the first one.

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

screenshots are not evidence, dates and documents are

What is the exact domain, character for character?

Correction: that domain is one character different from the one you posted, which is rather the point of this thread.

This. Decide in advance what you are watching for. Deciding in the middle of it is much harder.

Sent the same compound from Homopeptide and GL Biochem to Medutest in the same month. Both came back above the claim on the certificate — mine was 98.6% on a stated 98.0%.

Is there a quantity limit involved rather than a coverage refusal?

Regional stock made more difference to my planning than anything else — ordering from a warehouse in Sweden took the customs question off the table entirely.

Not quite. Two labs with different gradients can resolve a close-eluting impurity differently and both be reporting honestly.

Inter-lab variance on this assay runs a point or two either way.

Would qualify this slightly. Fewer entries means less sampling, and less sampling is not the same as a worse process.

Correction: that supplier is in the documented twenty with a source page, not in the wider-market table. Different evidence bases entirely.

Had the conversation with a clinician before stopping rather than after. Considerably easier that way round.

ask the pharmacy to check the wholesaler rather than guessing

Push back: the compounded arrangements changed and the advice you are quoting predates the change.

Stretching the interval or reducing the dose?

the source page log is more useful than the score above it

the interesting column is spread, not maximum

Asked SSA for the batch record on a Tuesday and had the full document, batch and method line, before the end of the day. That is the bar now.

Did you ask for the batch-specific document, or is this the catalogue one?

Yes, and the reason the wider-market table has no scores is that a score built on two reports would be a lie with a decimal point.

Merged into the standing thread for that domain so the reports sit in one place.

Adding the practical version: buy small from anyone new, test it, then decide.

Right — TFC publishes the method line on the certificate, and once you have seen one that does you notice every one that does not.

Regional stock made more difference to my planning than anything else — ordering from a warehouse in Ireland took the customs question off the table entirely.

Asked HJ for the batch-specific certificate and had the full document — batch, date, method line naming the column — inside six hours. That is now my baseline for everybody.

Area percent or net peptide content? They answer different questions.

The wider-market rows in the directory carry a band and a report count and nothing else, deliberately. Anything more would be manufacturing precision that the evidence does not support.

UV at 214nm sees the peptide bond and picks up almost everything; at 280nm you are looking at aromatics only.

This is the sentence to take away. The rest of the thread is footnotes to it.

a denial letter names a criterion, that is your handle

Agreed — the itemised related substances table is the difference between a document and a receipt.

Stretched from seven days to ten to twelve over four months. Appetite told me where the limit was each time.